tetano
Editor, Senior Moderator
Immunobiology. 2017 Oct 18. pii: S0171-2985(17)30181-X. doi: 10.1016/j.imbio.2017.10.040. [Epub ahead of print]
[h=1]Human monoclonal antibodies neutralizing influenza virus A/H1N1pdm09 and seasonal A/H1N1 strains - Distinct Ig gene repertoires with a similar action mechanism.[/h] Hiroi S[SUP]1[/SUP], Kuhara M[SUP]2[/SUP], Kishi Y[SUP]2[/SUP], Ono KI[SUP]2[/SUP], Matsuzawa S[SUP]2[/SUP], Yamamoto N[SUP]3[/SUP], Komano J[SUP]4[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Influenza virus causes acute respiratory infection in humans, and is a major public health concern globally. Antibodies play a central role in host protection against influenza virus. We isolated human monoclonal antibodies (hMAb) 206-2-4 and 201-6-8 by a human hybridoma protocol that neutralized various but distinct influenza virus (IFV) A/H1N1 strains, including 2009 pandemic strains. The half-inhibitory concentration of 206-2-4 and 201-6-8 against A/H1N1pdm09 strains was 2-100ng/mL and 5-20μg/mL, respectively. Prophylactic and therapeutic potencies of 206-2-4 were demonstrated in a mouse model of IFV infection at i.p. dosages of 0.25 and 2.5mg/kg, respectively, suggesting that 206-2-4 is one of the most potent hnMAbs against IFV reported thus far. The Ig genes of 206-2-4 and 201-6-8 were originated from distinct germ line repertoires, and accompanied by 63 and 23 somatic hypermutations, respectively. The hemagglutination inhibitory activity indicated that the mechanism of neutralization was to interfere the virus-receptor interaction. The binding epitope of the two antibodies was mapped to hemagglutinin 1 (HA1) amino acid residues 111-120. Additional interaction between the antibody and the HA1 globular head was necessary for neutralization. Such hnMAbs bearing distinct binding epitope have been rarely reported. The potency is likely due to the coverage of a wide surface area of HA protein by these hnMABs. IFV is a highly variable. Our knowledge on the mechanisms by which these cross-reactive hnMAbs function should help design a novel immunogen for the development of a vaccine effective against broader spectrum of IFV strains.
Copyright ? 2017 Elsevier GmbH. All rights reserved.
[h=4]KEYWORDS:[/h] Animal model; Cross-reactive; Epitope; Hemagglutinin; Human monoclonal antibody; Influenza virus; Neutralization
PMID: 29107382 DOI: 10.1016/j.imbio.2017.10.040
[h=1]Human monoclonal antibodies neutralizing influenza virus A/H1N1pdm09 and seasonal A/H1N1 strains - Distinct Ig gene repertoires with a similar action mechanism.[/h] Hiroi S[SUP]1[/SUP], Kuhara M[SUP]2[/SUP], Kishi Y[SUP]2[/SUP], Ono KI[SUP]2[/SUP], Matsuzawa S[SUP]2[/SUP], Yamamoto N[SUP]3[/SUP], Komano J[SUP]4[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Influenza virus causes acute respiratory infection in humans, and is a major public health concern globally. Antibodies play a central role in host protection against influenza virus. We isolated human monoclonal antibodies (hMAb) 206-2-4 and 201-6-8 by a human hybridoma protocol that neutralized various but distinct influenza virus (IFV) A/H1N1 strains, including 2009 pandemic strains. The half-inhibitory concentration of 206-2-4 and 201-6-8 against A/H1N1pdm09 strains was 2-100ng/mL and 5-20μg/mL, respectively. Prophylactic and therapeutic potencies of 206-2-4 were demonstrated in a mouse model of IFV infection at i.p. dosages of 0.25 and 2.5mg/kg, respectively, suggesting that 206-2-4 is one of the most potent hnMAbs against IFV reported thus far. The Ig genes of 206-2-4 and 201-6-8 were originated from distinct germ line repertoires, and accompanied by 63 and 23 somatic hypermutations, respectively. The hemagglutination inhibitory activity indicated that the mechanism of neutralization was to interfere the virus-receptor interaction. The binding epitope of the two antibodies was mapped to hemagglutinin 1 (HA1) amino acid residues 111-120. Additional interaction between the antibody and the HA1 globular head was necessary for neutralization. Such hnMAbs bearing distinct binding epitope have been rarely reported. The potency is likely due to the coverage of a wide surface area of HA protein by these hnMABs. IFV is a highly variable. Our knowledge on the mechanisms by which these cross-reactive hnMAbs function should help design a novel immunogen for the development of a vaccine effective against broader spectrum of IFV strains.
Copyright ? 2017 Elsevier GmbH. All rights reserved.
[h=4]KEYWORDS:[/h] Animal model; Cross-reactive; Epitope; Hemagglutinin; Human monoclonal antibody; Influenza virus; Neutralization
PMID: 29107382 DOI: 10.1016/j.imbio.2017.10.040